Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FST-100 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| FST-100 | EXPERIMENTAL | - |
| FST-100 Vehicle | PLACEBO_COMPARATOR | - |
| FST-100 (Component #1) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FST-100 | DRUG | FST-100 |
| FST-100 Vehicle | DRUG | FST-100 Vehicle |
| FST-100 (Component #1) | DRUG | 0.6% PVP-Iodine ophthalmic solution alone |
Inclusion Criteria: * Have a clinical diagnosis of suspected acute viral conjunctivitis in at least one eye Exclusion Criteria: * Have a known sensitivity to any of the components of FST-100 or FST-100 vehicle
FST-100 is an investigational small molecule being developed for the treatment of acute adenoviral conjunctivitis and acute viral conjunctivitis, which are eye infections causing inflammation of the conjunctiva. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
FST-100 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company listed on the Tokyo Stock Exchange under the ticker TAK. The drug is in Phase 2 clinical trials for acute viral and adenoviral conjunctivitis.
FST-100 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one for acute viral conjunctivitis and one for acute adenoviral conjunctivitis. The drug remains investigational and has not received regulatory approval.
FST-100 has been studied in two completed Phase 2 trials: NCT01461954 for acute viral conjunctivitis with 132 participants in the United States and Brazil, and NCT01470664 for acute adenoviral conjunctivitis with 176 participants in the United States and India. Both trials were randomized, double-blind, and placebo-controlled.
FST-100 is a small molecule designed to treat viral conjunctivitis, but its specific molecular target has not been disclosed. The drug is being evaluated for its ability to reduce the duration and severity of symptoms in patients with acute adenoviral or viral conjunctivitis.